公开(公告)号：US20150125441A1

公开(公告)日：2015-05-07

申请号：US14401202

申请日：2013-05-24

Applicant: NEW YORK UNIVERSITY

Inventor： Jing Wang ,  Edward Ziff

IPC: A61K31/453 ,  A61K45/06 ,  A61K31/4015

Abstract: The present invention provides methods of treating and pharmaceutical compositions useful for treating a mood disorder or depressive symptoms associated with pain, inducing analgesia and treating pain in a subject by administering a pharmaceutically effective amount of an agent capable of one or more of increasing GluA1 level, expression, concentration, or biological activity, increasing calcium permeable AMPA (α amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptor (CPAR) level, expression, concentration, or biological activity or potentiating a CPAR current. The agent may be an AMPA potentiator or ampakine. The agent may increase AMPA receptor currents by slowing the deactivation of open channels and may be, for instance, 2-pyrrolidinone, 4-[2-(phenylsulfonylamino)ethylthio]-2,6-difluorophenoxyacetamide (PEPA) or LY451646. The agent may also be a protein, RNA or DNA product.

Abstract translation: 本发明提供了治疗药物组合物和药物组合物的方法，所述药物组合物可用于治疗情绪障碍或与疼痛相关的抑郁症状，诱导镇痛和治疗受试者的疼痛，其通过施用药学有效量的能够增加GluA1水平， 表达，浓度或生物活性，增加钙渗透性AMPA（α氨基-3-羟基-5-甲基异恶唑-4-丙酸）受体（CPAR）水平，表达，浓度或生物活性或增强CPAR电流。 该药剂可以是AMPA增效剂或ampakine。 该试剂可以通过减缓开放通道的失活来增加AMPA受体电流，并且可以是例如2-吡咯烷酮，4- [2-（苯基磺酰基氨基）乙硫基] -2,6-二氟苯氧基乙酰胺（PEPA）或LY451646。 该试剂也可以是蛋白质，RNA或DNA产物。

公开(公告)号：US10702513B2

公开(公告)日：2020-07-07

申请号：US14401202

申请日：2013-05-24

Applicant: NEW YORK UNIVERSITY

Inventor： Jing Wang ,  Edward Ziff

IPC: A61K31/453 ,  A61K45/06 ,  A61K31/4015 ,  A61K31/275 ,  A61K31/42 ,  A61K31/7105 ,  A61K31/18

Abstract: The present invention provides methods of treating and pharmaceutical compositions useful for treating a mood disorder or depressive symptoms associated with pain, inducing analgesia and treating pain in a subject by administering a pharmaceutically effective amount of an agent capable of one or more of increasing GluA1 level, expression, concentration, or biological activity, increasing calcium permeable AMPA (α amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptor (CPAR) level, expression, concentration, or biological activity or potentiating a CPAR current. The agent may be an AMPA potentiator or ampakine. The agent may increase AMPA receptor currents by slowing the deactivation of open channels and may be, for instance, 2-pyrrolidinone, 4-[2-(phenylsulfonylamino)ethylthio]-2,6-difluorophenoxyacetamide (PEPA) or LY451646. The agent may also be a protein, RNA or DNA product.